Cooperative genetic defects in TLX3 rearranged pediatric T-ALL

Leukemia

Volumn 22, Issue 4, 2008, Pages 762-770

  Van Vlierberghe, P ^a   Homminga, I ^a   Zuurbier, L ^a   Gladdines Buijs, J ^a   van Wering, E R ^b   Horstmann, M ^c   Beverloo, H B ^d   Pieters, R ^a   Meijerink, J P P ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b Dutch Childhood Oncology Group DCOG   (Netherlands)

^c German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; HOMEODOMAIN PROTEIN; MYC PROTEIN; NOTCH1 RECEPTOR; PROTEIN C JUN; PROTEIN FBXW7; PROTEIN TLX3; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; T CELL LEUKEMIA;

EID: 42349111493     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405082     Document Type: Article

References (58)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Clappier E, Cuccuini W, Cayuela JM, Vecchione D, Baruchel A, Dombret H et al. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia 2006; 20: 82-86.
3. De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica 2005; 90: 1116-1127.
4. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084-1089.
5. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007; 39: 593-595.
6. Soulier J, Clappier E, Cayuela JM, Regnault A, Garcia-Peydro M, Dombret H et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005; 106 274-286.
7. Speleman F, Cauwelier B, Dastugue N, Cools J, Verhasselt B, Poppe B et al. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia 2005; 19: 358-366.
8. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006; 108: 3520-3529.
9. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
10. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007; 110: 1251-1261.
11. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: From thymocyte to lymphoblast. Leukemia 2006; 20: 1496-1510.
12. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 6306-6315.
13. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6: 347-359.
14. Bernard OA, Busson-LeConiat M, Ballerini P, Mauchauffe M. Delia Valle V. Monni R et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001; 15: 1495-1504.
15. Hansen-Hagge TE, Schafer M, Kiyoi H, Morris SW, Whitlock JA, Koch P et al. Disruption of the RanBP17/Hox11L2 region by recombination with the TCRdelta locus in acute lymphoblastic leukemias with t(5;14)(q34;q11). Leukemia 2002; 16: 2205-2212.
16. Su XY, Busson M. Della Valle V, Ballerini P, Dastugue N, Talmant P et al. Various types of rearrangements target TLX3 locus in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2004; 41: 243-249.
17. van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: A retrospective study of patients treated according to DCOG or COALL protocols. Haematologica 2006; 91: 1212-1221.
18. Berger R, Dastugue N, Busson M, Van Den Akker J, Perot C, Ballerini P et al. t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Leukemia 2003; 17: 1851-1857.
19. Mauvieux L, Leymarie V, Helias C, Perrusson N, Falkenrodt A, Lioure B et al. High incidence of Hox11L2 expression in children with T-ALL. Leukemia 2002; 16: 2417-2422.
20. Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 2002; 100: 991-997.
21. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A et al Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Results of EORTC studies 58881 and 58951. Blood 2004; 103: 442-450.
22. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD et al. Global variation in copy number in the human genome. Nature 2006; 444: 444-454.
23. Waggoner DJ, Raca G, Welch K, Dempsey M, Anderes E, Ostrovnaya I et al, NSD1 analysis for Sotos syndrome: Insights and perspectives from the clinical laboratory. Genet Med 2005; 7: 524-533.
24. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukmia 2007 Oct 11 (advance online publication).
25. Malyukova A, Dohda T, von der Lehr N, Akhondi S, Corcoran M, Heyman M et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611-5616.
26. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007; 447: 966-971.
27. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204 1813-1824.
28. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835.
29. Balgobind B, Van Vlierberghe P, van den Ouweland A, Beverloo HB, Terlouw-Kromosoeto J, van Wering ER et al. Leukemia associated NF1 inactivation in pediatric T-ALL and AML patients lacking evidence for neurofibromatosis. Blood 2007 (in press).
30. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: The WT1 story. Leukemia 2007; 21: 868-876.
31. Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T et al Haploinsufficiency of NSD1 causes Sotos syndrome. Nature genetics 2002; 30: 365-366.
32. Al-Mulla N, Belgaumi AF, Teebi A. Cancer in Sotos syndrome: Report of a patient with acute myelocytic leukemia and review of the literature. J Pediatr Haematol Oncol 2004; 26: 204-208.
33. Martinez-Glez V, Lapunzina P. Sotos syndrome is associated with leukemia/ lymphoma. Am J Med Genet A 20071; 143: 1244-1245.
34. Ziino O, Rondelli R, Micalizzi C, Luciani M, Conter V, Arico M. Acute lymphoblastic leukemia in children with associated genetic conditions other than Down's syndrome. The AIEOP experience. Haematologica 2006; 91: 139-140.
35. Brown J, Jawad M, Twigg SR, Saracoglu K, Sauerbrey A, Thomas AE et al A cryptic t(5;11)(q35;p15.5) in 2 children with acute myeloid leukemia with apparently normal karyotypes, identified by a multiplex fluorescence in situ hybridization telomere assay. Blood 2002; 99: 2526-2531.
36. Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B et al. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res 2006; 12: 131-138.
37. Kim MY, Yim SH, Kwon MS, Kim TM, Shin SH, Kang HM et al. Recurrent genomic alterations with impact on survival in colorectal cancer identified by genome-wide array comparative genomic hybridization. Gastroenterology 2006; 131: 1913-1924.
38. Mori N, Morosetti R, Mizoguchi H, Koeffler HP. Progression of myelodysplastic syndrome: Allelic loss on chromosomal arm 1p. Br J Haematol 2003; 122: 226-230.
39. Mori N, Morosetti R, Spira S, Lee S, Ben-Yehuda D, Schiller G et al Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 1998; 92: 3405-3409.
40. Melendez B, Cuadros M, Robledo M, Rivas C, Fernandez-Piqueras J, Martinez-Delgado B et al. Coincidental LOH regions in mouse and humans: Evidence for novel tumor suppressor loci at 9q22-q34 in non-Hodgkin's lymphomas. Leuk Res 2003; 27: 627-633.
41. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007; 128: 459-475.
42. Fischer A, Gessler M. Delta-Notch-and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 2007; 35: 4583-4596.
43. Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science (New York, NY 1996; 274: 990-992.
44. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949.
45. Plantier I, Lai JL, Wattel E, Bauters F, Fenaux P. Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: A report on 19 cases with prolonged follow-up. Leuk Res 1994; 18: 885-888.
46. Betts DR, Ammann RA, Hirt A, Hengartner H, Beck-Popovic M, Kuhne T et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol 2007; 78: 468-476.
47. Filippova GN, Fagerlie S, Klenova EM, Myers C, Dehner Y, Goodwin G et al. An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol 1996; 16: 2802-2813.
48. Inaba T, Murakami S, Oku N, Itoh K, Ura Y, Nakanishi S et al. Translocation between chromosomes 8q24 and 14q11 in T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 1990; 49: 69-74.
49. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006; 103: 18261-18266.
50. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20: 2096-2109.
51. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
52. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997; 9: 209-225.
53. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961-2968.
54. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 1996; 87: 2171-2179.
55. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405-409.
56. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970-977.
57. Barragan E, Cervera J, Bolufer P, Ballester S, Martin G, Fernandez P et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926-933.
58. Chiusa L, Francia di Celle P, Campisi P, Ceretto C, Marmont F, Pich A. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. Haematologica 2006; 91: 270-271.